Early access to experimental SMA drug apitegromab offered before approval
NCT ID NCT06877689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program provides apitegromab, an experimental drug that blocks myostatin to help maintain muscle strength, to eligible patients with spinal muscular atrophy (SMA) before it is officially approved. Participants must be at least 2 years old and have a confirmed diagnosis of 5q SMA. The program aims to offer treatment to those who cannot join other clinical trials and for whom the potential benefit outweighs the risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apitegromab (a monoclonal antibody that blocks myostatin activation to help maintain muscle strength)
- What this could lead to
- If successful, this program could provide early access to a treatment that helps preserve muscle function in people with spinal muscular atrophy.
- What could go wrong
- This is an expanded access program, not a full clinical trial, so data on safety and effectiveness are still limited. Apitegromab is investigational and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 5Q SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug shows promise for SMA patients in major trial
- One-Time gene therapy helps babies with fatal muscle disease sit independently
- Swiss launch major registry to track rare muscle diseases
- New Muscle-Boosting drug shows promise for SMA patients in major trial
- French SMA questionnaire put to the test: will it measure up?
- New drug hopes to boost muscle power in babies with SMA